BillionToOne, Inc. (BLLN)

Market Cap	5.07B
Revenue (ttm)	209.03M
Net Income (ttm)	-30.62M
Shares Out	45.40M
EPS (ttm)	-2.99
PE Ratio	n/a
Forward PE	500.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	167,946
Open	105.13
Previous Close	104.02
Day's Range	104.03 - 118.00
52-Week Range	88.00 - 138.70
Beta	n/a
Analysts	Buy
Price Target	138.67 (+24.21%)
Earnings Date	Dec 9, 2025

About BLLN

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and type...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 6, 2025
• Employees: 620
• Stock Exchange: NASDAQ
• Ticker Symbol: BLLN
• Website: https://www.billiontoone.com

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 6 analysts, the average rating for BLLN stock is "Buy." The 12-month stock price target is $138.67, which is an increase of 24.21% from the latest price.

Price Target

$138.67

(24.21% upside)

Analyst Consensus: Buy